(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 September 2021 (23.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/185821 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61P 3/10* (2006.01)
A61K 9/08 (2006.01) *A61K 47/02* (2006.01)
A61K 38/26 (2006.01) *A61K 47/18* (2017.01)
A61P 3/04 (2006.01)

(21) International Application Number:
PCT/EP2021/056651

(22) International Filing Date:
16 March 2021 (16.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20163408.6 16 March 2020 (16.03.2020) EP

(71) Applicant: **ZEALAND PHARMA A/S** [DK/DK]; Sydmarken 11, DK-2860 Søborg (DK).

(72) Inventors: **VILLADSEN, Jesper Skodborg**; Sydmarken 11, DK-2860 Søborg (DK). **GOTTSCHALK BØVING, Tine Elisabeth**; Sydmarken 11, DK-2860 Søborg (DK).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol Bristol BS1 6BX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: LIQUID FORMULATIONS OF GLUCAGON ANALOGUES

(57) Abstract: The present invention relates to formulations of glucagon analogues, or a pharmaceutically acceptable salt thereof and/or a derivative thereof; and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising combinations of excipients that make them suitable for long term storage as liquids, and are capable of use in single-dose (SD) or multi-dose (MD) formulations.

WO 2021/185821 A1